Toshiba Medical’s AplioTM i900 cardiovascular ultrasound receives US FDA clearance

Toshiba Medical Aplio i900

Cardiologists can now access the advanced ultrasound imaging technology needed for fast and confident diagnoses with Toshiba Medical’s Aplio i900. The newly US Food and Drug Administration (FDA)-cleared system is the latest addition to the premium Aplio i-series ultrasound platform.

According to a company release, the Aplio i900 is intended to bring “ultra-premium” cardiac imaging to an everyday clinical setting, offering healthcare facilities a more cost-effective, less invasive and safer solution than other radiation-emitting modalities. The system boasts innovative features that allow clinicians to quickly and easily assess myocardial function or to quantify complex valvular lesions with greater depth and detail.

Designed to suit contrast, foetal, paediatric, stress echo and transesophageal echocardiography imaging, the Aplio i900 is intended to deliver extreme processing power, helping healthcare providers to see more in their ultrasound exams due to thinner beam slices and more return information in each image.

A new beam-forming technology, iBeam, has been developed in order to optimise efficiency of the beam which, according to a press release, increases penetration, spatial resolution and contrast resolution. The release also states that the system can boost productivity during exams, providing intuitive ergonomics with iSense and touch control screens. The device’s real-time quick scan is designed to make automatic image adjustments without the need to push a button.